MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform
News Mar 25, 2010
MDRNA, Inc, a leading RNAi-based drug discovery and development company, announced today that it has acquired intellectual property for bridged nucleic acids from Valeant Pharmaceuticals North America. Bridged nucleic acids (BNA) are novel nucleoside analogs in which the flexible ribose sugar is locked into a rigid conformation by a small chemical linker. When included in single or double stranded oligonucleotides, the highly stable A-form of RNA or DNA is favored, resulting in increased thermal stability of a duplex or higher affinity of a single strand for its complementary target, e.g., messenger RNA. In addition BNAs provide resistance to nuclease degradation.
"The BNA technology provides MDRNA a unique position in the development of RNA therapeutics," stated Barry Polisky, Chief Scientific Officer of MDRNA. "BNA is highly complementary to our proprietary unlocked nucleobase analog (UNA) technology and enables MDRNA to tailor key characteristics of our UsiRNA constructs to impart greater versatility and specificity. Additionally, BNA strengthens MDRNA's proprietary meroduplex constructs and are directly applicable to alternative oligonucleotide constructs including single strand molecules and constructs which function outside of an RNAi mechanism."
The patent estate offers MDRNA considerable breadth in the research and development of nucleic acid-based therapies to include not only those with an RNAi mechanism of action, such as siRNA and miRNA, but those that function to inhibit RNA by a diverse set of mechanisms.
"We are focused on becoming the preeminent RNAi-based therapeutics company," stated J. Michael French, President and CEO of MDRNA. "The addition of this key intellectual property places us in a position to provide a broader array of RNAi-based drug discovery technologies to potential pharmaceutical partners and allows us entry into an important emerging therapeutic space driven by single stranded RNA constructs."
With the addition the of the BNA patent estate, MDRNA owns or controls 15 issued or allowed patents, and has 37 pending patent applications, 126 pending foreign patent applications and 7 PCT applications.
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Who Owns the Ocean? One Company Has Registered Half of All Marine Gene PatentsNews
A single corporation has registered nearly half of all existing patents associated with genes from marine organisms, according to a new study. Researchers from the University of British Columbia and the Stockholm Resilience Centre examined the patents associated with marine species and found that BASF, the world’s largest chemical manufacturer, has registered 47 per cent of the 12,998 genetic sequences from 862 marine species.